Avalyn Pharma Inc. (NASDAQ:AVLN) Given Consensus Rating of “Buy” by Analysts

Shares of Avalyn Pharma Inc. (NASDAQ:AVLN) have been given an average rating of “Buy” by the five ratings firms that are covering the company, MarketBeat Ratings reports. One analyst has rated the stock with a hold rating, two have given a buy rating and two have issued a strong buy rating on the company. The average 1-year target price among brokers that have updated their coverage on the stock in the last year is $59.00.

A number of equities research analysts have issued reports on the stock. Jefferies Financial Group began coverage on shares of Avalyn Pharma in a research report on Monday, May 25th. They issued a “buy” rating and a $52.00 price objective for the company. Evercore began coverage on shares of Avalyn Pharma in a research report on Tuesday, May 26th. They set an “outperform” rating and a $51.00 target price on the stock. Wall Street Zen upgraded Avalyn Pharma to a “hold” rating in a research note on Saturday, May 9th. Guggenheim started coverage on Avalyn Pharma in a report on Monday, May 25th. They issued a “buy” rating and a $80.00 target price for the company. Finally, Zacks Research raised Avalyn Pharma to a “hold” rating in a research report on Wednesday, May 27th.

Insiders Place Their Bets

In related news, Director Jill Carroll purchased 277,778 shares of Avalyn Pharma stock in a transaction that occurred on Friday, May 1st. The stock was bought at an average price of $18.00 per share, for a total transaction of $5,000,004.00. Following the completion of the transaction, the director owned 2,186,562 shares in the company, valued at $39,358,116. This represents a 14.55% increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, major shareholder Sr One Capital Management, Llc acquired 555,555 shares of the firm’s stock in a transaction that occurred on Friday, May 1st. The shares were bought at an average price of $18.00 per share, with a total value of $9,999,990.00. Following the acquisition, the insider directly owned 2,186,562 shares of the company’s stock, valued at $39,358,116. The trade was a 34.06% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure.

Avalyn Pharma Stock Performance

NASDAQ AVLN opened at $27.95 on Friday. Avalyn Pharma has a 1 year low of $24.15 and a 1 year high of $33.32. The company has a market cap of $1.24 billion and a price-to-earnings ratio of -1.28. The business has a fifty day moving average price of $28.74.

Avalyn Pharma (NASDAQ:AVLN) last announced its earnings results on Wednesday, June 3rd. The company reported ($21.83) EPS for the quarter, missing the consensus estimate of ($16.38) by ($5.45).

About Avalyn Pharma

We are a clinical-stage biopharmaceutical company pioneering inhaled therapies to transform the treatment paradigm of serious, rare respiratory diseases with significant unmet needs. Our approach is designed to address the limitations of current oral therapies by delivering optimized inhaled formulations of approved oral medicines directly to the lungs to enhance efficacy and minimize systemic exposure that contributes to side effects and treatment discontinuation. Our current pipeline is focused on treating pulmonary fibrosis, a life-threatening disease with a median survival of three to five years, which is a significantly shorter prognosis than that observed for many forms of cancer.